| 1 |
33830080 | The CRTC1-MAML2 fusion is the major oncogenic driver in mucoepidermoid carcinoma. | 2021 Apr 8 |
1 |
| 2 |
27004400 | MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. | 2016 Apr 26 |
3 |
| 3 |
24351425 | ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition. | 2014 Mar 1 |
1 |
| 4 |
24827134 | Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. | 2014 Jul |
2 |
| 5 |
24114668 | Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. | 2013 Dec 1 |
2 |
| 6 |
18980991 | Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. | 2008 Nov 1 |
1 |